Literature DB >> 28653902

NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer.

Behrad Darvishi1, Leila Farahmand1, Zahra Eslami-S1, Keivan Majidzadeh-A2.   

Abstract

Graphical abstract Although accounting for merely a minute portion of diagnosed breast cancers, disproportionate number of deaths and associated low survival rate of patients have made triple-negative breast cancer to be considered as the most lethal breast cancer subtype. More importantly, intrinsic or developed resistance to chemotherapeutic regimens and disappointing outcomes of trials associated with many newly developed agents are other obstacles in establishment of a durable response in these patients. Interestingly, these happen despite the outstanding preclinical outcomes observed by these agents, most importantly among them, targeted receptor tyrosine kinase inhibitors. Pursuing these disappointing outcomes, especially in the case of targeted receptor tyrosine kinase inhibitors, many researches have focused on identification of the hidden factors involved. Highly inflammatory, rich in reactive oxygen species, and hypoxic microenvironment of triple-negative breast cancer tumors and the involving mediators were the first suggestions for observed resistance and poor clinical outcomes of targeted receptor tyrosine kinase inhibitors. Interestingly, for all aberrantly expressed mediators observed in microenvironment, downstream pathways converge in a common node, nothing but the nuclear factor-κB, the insidious factor proposed to be the cause of many events opposing achievement of a desired outcome. In first section of current review, we describe the signaling pathways underlying activation of receptor tyrosine kinases and their convergence at the nuclear factor-κB node, and in next section, we demonstrate how unique hypoxic, inflammatory, rich in free-radical microenvironment of triple-negative breast cancer exacerbate pathways in which otherwise could become mostly suppressed by receptor tyrosine kinase inhibitors.

Entities:  

Keywords:  Triple-negative breast cancer; chemotherapy resistance; nuclear factor-κB; receptor tyrosine kinase inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28653902     DOI: 10.1177/1010428317706919

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  12 in total

Review 1.  Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance.

Authors:  Behrad Darvishi; Mohammad Reza Eisavand; Keivan Majidzadeh-A; Leila Farahmand
Journal:  Br J Cancer       Date:  2022-02-05       Impact factor: 9.075

2.  Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Authors:  Grazia Ambrosini; Catherine Do; Benjamin Tycko; Ronald B Realubit; Charles Karan; Elgilda Musi; Richard D Carvajal; Vivian Chua; Andrew E Aplin; Gary K Schwartz
Journal:  Cancer Res       Date:  2019-03-18       Impact factor: 13.312

Review 3.  PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.

Authors:  Henan Zhao; Duojiao Li; Baojing Zhang; Yan Qi; Yunpeng Diao; Yuhong Zhen; Xiaohong Shu
Journal:  Molecules       Date:  2017-12-20       Impact factor: 4.411

Review 4.  The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.

Authors:  Getinet M Adinew; Equar Taka; Patricia Mendonca; Samia S Messeha; Karam F A Soliman
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

5.  RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.

Authors:  Adrián Sanz-Moreno; Sonia Palomeras; Kim Pedersen; Beatriz Morancho; Tomas Pascual; Patricia Galván; Sandra Benítez; Jorge Gomez-Miragaya; Marina Ciscar; Maria Jimenez; Sonia Pernas; Anna Petit; María Teresa Soler-Monsó; Gemma Viñas; Mansour Alsaleem; Emad A Rakha; Andrew R Green; Patricia G Santamaria; Celine Mulder; Simone Lemeer; Joaquin Arribas; Aleix Prat; Teresa Puig; Eva Gonzalez-Suarez
Journal:  Breast Cancer Res       Date:  2021-03-30       Impact factor: 6.466

6.  PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism.

Authors:  Luca Simula; Ylenia Antonucci; Giorgia Scarpelli; Valeria Cancila; Alessandra Colamatteo; Simona Manni; Biagio De Angelis; Concetta Quintarelli; Claudio Procaccini; Giuseppe Matarese; Claudio Tripodo; Silvia Campello
Journal:  Mol Oncol       Date:  2021-10-14       Impact factor: 6.603

Review 7.  Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression.

Authors:  Jan Ježek; Katrina F Cooper; Randy Strich
Journal:  Antioxidants (Basel)       Date:  2018-01-16

8.  Relationship between expression of CXCR7 and NF-κB in breast cancer tissue and occurrence of breast cancer and lymphatic metastasis.

Authors:  Cheng-Liang Yuan; Zhao-Hong Liu; Ning Zou; Ya-Li Wang; Zhong-Yao Chen
Journal:  Saudi J Biol Sci       Date:  2017-11-10       Impact factor: 4.219

9.  Repurposing of Bromocriptine for Cancer Therapy.

Authors:  Ean-Jeong Seo; Yoshikazu Sugimoto; Henry Johannes Greten; Thomas Efferth
Journal:  Front Pharmacol       Date:  2018-10-08       Impact factor: 5.810

10.  Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors.

Authors:  Parnaz Merikhian; Behrad Darvishi; Neda Jalili; Mohammad Reza Esmailinejad; Azadeh Sharif Khatibi; Shima Moradi Kalbolandi; Malihe Salehi; Marjan Mosayebzadeh; Mahdieh Shokrollahi Barough; Keivan Majidzadeh-A; Fatemeh Yadegari; Fatemeh Rahbarizadeh; Leila Farahmand
Journal:  Mol Oncol       Date:  2021-11-19       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.